Michael Moran , PhD
Research Institute
Senior Scientist
Molecular Structure & Function
Director
Advanced Protein Technology Centre
University of Toronto
Director, Drug Discovery Program
McLaughlin Centre for Molecular Medicine
Professor
Medical Genetics, and Banting and Best Department of Medical Research
Chair Positions
Canada Research Chair
Molecular Therapeutics
Phone: 647-235-6435
Fax: 416-813-8456
e-mail: m.moran@utoronto.ca
Alternate Contact: Donna DeFrancesco
Alternate Phone: 416-581-7853
Alternate e-mail: ddefranc@uhnresearch.ca
Brief Biography
Dr. Moran completed his PhD in Biochemistry at the National Cancer Institute of Canada’s Cancer Research Laboratory at the University of Western Ontario in 1987. He was an NCIC Fellow at Mount Sinai Hospital (1986-1990), and then joined the University of Toronto in 1990 in the Banting and Best Department of Medical Research, and the Department of Molecular and Medical Genetics. He was an NCIC Scientist from 1991-97 and an MRC/Canadian Institutes for Health Research Scientist from 1997-2002.
Dr. Moran has served on various granting agency study sections related to cancer, and consulted and collaborated with pharmaceutical and biotechnology companies in the area of drug discovery. He helped found the companies Ocata Proteomics and MDS Proteomics, and served as Chief Scientific Officer.
Dr. Moran’s research focus, publications, and invited seminars have addressed the intracellular signaling networks that control growth, survival, and spreading of tumours, and how drugs may be designed to target key components in these molecular networks. His group uses proteomics technologies including mass spectrometry and bioinformatics to identify and characterize proteins activated in cancers, and to determine drug mechanisms of action.
External Funding
- Canadian Cancer Society Research Institute
- Canadian Institutes of Health Research
- Canadian Foundation for Innovation
- Ontario Institute for Cancer Research
- Ontario Research Fund
- National Institutes of Health/National Cancer Institute
Publications
St-Germain JR, Taylor P, Tong J, Jin LL, Nikolic A, Stewart II, Ewing RM, Dharsee M, Li Z, Trudel S, Moran MF. (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A, 106(47):20127-32
Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A. (2009) Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 69(19):7548-56
Tong J, Taylor P, Peterman SM, Prakash A, Moran MF. (2009) EGF receptor phosphorylation sites S991 and Y998 are implicated in the regulation of receptor endocytosis, protein-protein interactions, and p38 MAPK-dependent phosphorylation at S1039 and T1041. Mol. Cell. Proteomics, doi: 10.1074
Taylor P, Neilsen PA, Trelle MB, Horning OB, Andersen MB, Vorm O, Moran MF, Kislinger T. (2009) Automated 2D peptide separation on a 1D Nano-LC-MS system. J Prot Res 8(3):1610-1616
Iliadi KB, Avivi A, Iliadi NN, Korol AB, Nevo E, Knight D, Taylor P, Moran MF, Kamyshev NG, Boulianne GL. (2008) Nemy, the Drosophila homology of cytochrome b561, is required for Drosophila memory formation and regulates PHM activity. PNAS 105(50) 19986-91
Tong J, Taylor P, Jovceva E, St-Germain JR, Jin LL, Nikolic A, Gu X, Li ZH, Trudel S, Moran MF. (2008) Tandem Immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19orf19 becomes tyrosine phosphorylated and associated with activated epidermal growth factor receptor. J. Proteome Research, 7(3):1067-1077
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Ethier M, Abu-Farha M, Lambert JP, Duewel HS, Sterwart II, Kuehl B, Boutilier K, Colwil K, Haberstroh K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglu T, Figeys D. (2007) Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Systems Biol. 3:89 doi:10.1038
Moran MF, Tong J, Taylor P, Ewing RM. (2006) Emerging applications for phospho-proteomics in cancer molecular therapeutics. Biochim Biophys Acta (Rev. Cancer) 1766(2):230-41
Stover D, Caldwell J, Marto J, Root K, Mestan J, Stumm M, Ornatsky O, Orsi C, Radosevic N, Liao L, Fabbro D, Moran MJ. (2004) Differential phosphoprofiles of EGF and EGFR kinase inhibitor treated human tumor cells and mouse xenografts. Clinical Proteomics, 1:69-80
Toledo-Sherman LM, Desouza L, Hosfield D, Liao L, Botillier K, Taylor P, Climie S, McBroom L, Moran MF. (2004) New targets for an old drug: a chemical proteomics approach to unraveling the molecular mechanism of action of methotrexate. Clinical Proteomics 1:45-68
Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P, Bennett K, Boutilier K, Yang L, Wolting C, Donaldson I, Schandorff S, Shewnarane J, Vo M, Taggart J, Goudreault M, Muskat B, Alfarano C, Dewar D, Lin Z, Michalickova K, Willems AR, Sassi H, Nielsen PA, Rasmussen KJ, Andersen JR, Johansen LE, Hansen LH, Jespersen H, Podtelejnikov A, Nielsen E, Crawford J, Poulsen V, Sorensen BD, Matthiesen J, Hendrickson RC, Gleeson F, Pawson T, Moran MF, Durocher D, Mann M, Hogue CW, Figeys D, Tyers M. Related Articles. (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature. 415(6868):180-3.